C12Y 207/10
Protein-tyrosine kinases
Official title: Protein-tyrosine kinases (2.7.10)
C12Y207/10 (Protein-tyrosine kinases) appears on 280 US grants and 592 published applications in this corpus.
Search patents in C12Y- Granted patents
- 280
- Published applications
- 592
- Assignees
- 323
- Inventors
- 1,226
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 6 |
| 2006 | 0 | 3 |
| 2007 | 1 | 4 |
| 2008 | 3 | 4 |
| 2009 | 1 | 7 |
| 2010 | 2 | 14 |
| 2011 | 6 | 11 |
| 2012 | 7 | 14 |
| 2013 | 9 | 12 |
| 2014 | 9 | 19 |
| 2015 | 13 | 47 |
| 2016 | 18 | 53 |
| 2017 | 26 | 44 |
| 2018 | 22 | 44 |
| 2019 | 25 | 31 |
| 2020 | 25 | 31 |
| 2021 | 25 | 35 |
| 2022 | 19 | 52 |
| 2023 | 12 | 42 |
| 2024 | 19 | 44 |
| 2025 | 23 | 46 |
| 2026 | 15 | 28 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- NGF antagonists for medical use11 Aug 2026US 12,703,753 B2Elanco US Inc.
- Methods of treating cancers containing fusion genes28 Jul 2026US 12,692,547 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Compositions and methods related to megakaryocyte-derived extracellular vesicles for treating myeloproliferative neoplasms2 Jun 2026US 12,644,134 B2STRM.bio Incorporated
- Treatment of ocular neovascularization using anti-vegf proteins26 May 2026US 12,636,348 B2Avalanche Australia Pty Ltd.
- Peptide inhibitors of focal adhesion kinase activity and uses thereof26 May 2026US 12,637,492 B2Arizona Board of Regents on Behalf of the University of Arizona
- Multi-target drug conjugate and use thereof for cancer treatment1 Oct 2026US 2026/0295061 A1Virginia Tech Intellectual Properties, Inc.
- Optogenetic activation for signal transduction17 Sep 2026US 2026/0274903 A1The Chinese University of Hong Kong
- Chk1-targeting sirnas chemically modified with gemcitabine10 Sep 2026US 2026/0265754 A1Sirnaomics, Inc.
- Engineered natural killer cells with enhanced antitumor memory responses3 Sep 2026US 2026/0258360 A1Board of Regents, The University of Texas System
- Antibodies and uses thereof27 Aug 2026US 2026/0250421 A1Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Most cited
By later US patents
- Truncated epiderimal growth factor receptor (EGFRt) for transduced T cell selection117US 8,802,374 B2City of Hope · 2014
- Inhibition of Syk kinase expression50US 7,173,015 B2The Trustees of the University of Pennsylvania · 2007
- Azaindoles useful as inhibitors of janus kinases41US 7,767,816 B2Vertex Pharmaceuticals Incorporated · 2010
- Mutant-selective EGFR inhibitors and uses thereof40US 8,796,255 B2Celgene Avilomics Research, Inc. · 2014
- Azaindoles useful as inhibitors of Janus kinases23US 8,163,917 B2Vertex Pharmaceuticals Incorporated · 2012